KMT2A and neoplasm: Indeed, the anti-CD19 TM combined with this EM is capable of lysing CD19 positive tumor cells (Supplemental Figure 1B) including from patients with mixed lineage leukemia (MLL) or acute lymphoblastic leukemia (ALL) both in an hetero- and autologous setting (Supplemental Figure 1C).